Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
93 hedge funds and large institutions have $888M invested in Adaptimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 11 closing their positions.
303% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $2.56M
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
34% more capital invested
Capital invested by funds: $663M → $888M (+$225M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
8% more funds holding
Funds holding: 86 → 93 (+7)
1.68% more ownership
Funds ownership: 9.88% → 11.57% (+1.7%)
50% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$65.8M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$26.2M |
| 3 |
Millennium Management
New York
|
+$13.9M |
| 4 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$5.93M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$5.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.4M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.28M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$5.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$4.13M |
| 5 |
Renaissance Technologies
New York
|
-$2.81M |
ADAP Hedge Fund Activity: Q3 2018 in Review
93 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2018, worth a combined $888M — up 34% from $663M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ADAP positions and 11 closed out — a net gain of 7 holders — while 18 added to existing stakes and 36 trimmed.
The largest buyer was Matrix Capital Management Company, adding an estimated $65.8M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.
- 93 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2018, up from 86 in Q2 2018.
- Funds reported $888M of Adaptimmune Therapeutics stock for Q3 2018, up 34% quarter-over-quarter.
- 18 funds opened new Adaptimmune Therapeutics positions in Q3 2018 and 11 closed out, a net change of +7 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2018 was Matrix Capital Management Company, an estimated $65.8M added.
- The largest Adaptimmune Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2018.